Health Care Sector

Weight-loss drugs and other innovations have created exciting opportunities.

Eddie Yoon | Sector Portfolio Manager

Key Takeaways

  • The main headline in the health care sector in the past year was the excitement surrounding a new category of weight-loss drugs.
  • This innovation drove gains among some stocks but losses among some providers of traditional treatments for diabetes and obesity.
  • In 2023, valuations have continued to reset lower across much of the sector, which has created some interesting opportunities as we look forward into 2024 and beyond.
  • In addition to shifts driven by weight-loss drugs, there may be compelling potential among managed-care providers, as the US health insurance market undergoes long-term change.

2023 may be remembered as a groundbreaking year for the health care sector, due to the excitement surrounding promising new weight-loss drugs that have quickly become highly sought after worldwide. It may also be remembered as a year that divided major perceived "winners" and "losers" of these developments—with investors rewarding drug innovators and punishing some providers of traditional treatments for diabetes and obesity.

For 2024, it's impossible to predict what stocks or segments investors may favor. But the health care sector could have a strong setup, given recently low valuations and powerful long-term innovations and trends that may continue to play out.

A year of innovation

Just as investor excitement over artificial intelligence drove returns in the technology and communication services sectors during 2023, investor enthusiasm for weight-loss drugs was a key driver behind health care stock returns over the year.

On the upside, stocks of the producers of these drugs experienced significant gains. On the downside, some stocks of health care equipment makers that serve the diabetes market—such as makers of insulin pumps—experienced losses as investors became concerned over how weight-loss drugs might hurt long-term demand for diabetes devices.

Health care utilization also ticked higher as patients who delayed surgeries and treatment during the pandemic continued to seek services in hospitals, doctor offices, and ambulatory care centers in increased numbers. This generally supported groups like health care facilities and medical-device manufacturers, but weighed on the stocks of managed-care health insurers.

More important to sector-level returns, health care as a whole was simply not in favor with investors in 2023. Health care stocks tend to be viewed as defensive, given that people generally go to the doctor and take their medications regardless of what's going on in the economy. This reputation was a disadvantage in 2023 as investors favored mega-cap growth stocks (particularly those of large tech companies seen as potential plays on artificial intelligence), over defensive sectors. This fueled the sector's overall lagging returns.

S&P 500HEALTH CARE SECTORFeb.MarchAprilMayJuneJulyAug.Sept.Oct.Nov.Jan.8090100110120Year-to-date price returnIndexed value+19.9%–3.1%

Attractive valuations and long-term potential

Looking ahead, the performance of health care stocks may be heavily influenced by the direction of the broader economy and the current starting point of valuations. While I can't be sure of where the economy is headed, the low starting point of valuations may be a positive for the sector.

The new-generation weight-loss drugs, may transform how both diabetes and obesity are treated. The potential market for these drugs is extensive: An estimated 38 million Americans have diabetes (with almost 9 million of those cases estimated to be undiagnosed).1 Some 60 million European adults are estimated to have diabetes,2 while the prevalence in developing markets has been rising. Meanwhile, there are estimated to be more than 500 million obese adults globally.3 As a result, these new weight-loss drugs (which are known as glucagon-like peptide-1, or GLP-1, agonists), could be a large class of drugs for the world for an extended period.

However, investors may have underestimated how long it will take for these drugs to be broadly adopted, and how long it will take for them to potentially hurt demand for existing diabetes and obesity treatments. This has created some interesting opportunities in areas of the market that underperformed on GLP-1 exuberance, such as makers of insulin pumps and devices treating sleep apnea. I have also found potential opportunity in firms that support the diabetes and obesity drug market, including life sciences tools and services companies which make key components for these injectable medicines.

Another long-term trend I have continued to find interesting is the transformation in health insurance. In the US, a gradual transition has been underway, from a traditional fee-for-service model (in which providers are compensated based on the volume of visits and services they provide) to a value-based model (in which physicians are compensated based on patient outcomes rather than on service volumes). While stocks of managed-care companies were hampered in the past year by some of the short-term headwinds mentioned above, some could be poised to benefit from this long-term transformation.

A focus on the long term

No matter where US markets are headed next, the health care sector can offer a combination of defensive and growth characteristics that may be attractive in a variety of scenarios. But my focus remains on the long term—that is, trying to invest in the most innovative areas of health care, where Fidelity's research insights may help deliver material value over time.

More 2024 Equity Sector Outlooks


There was an issue with your input


Please confirm